Caris Life Sciences is a cancer diagnostics company that develops advanced molecular profiling and AI-based technologies to drive precision oncology. Its flagship offering, Caris Molecular Intelligence, analyzes DNA, RNA, and protein data to help oncologists personalize treatment plans. The company also offers CODEai, a platform that combines molecular insights with clinical outcomes to accelerate research and drug discovery. Caris partners with biopharma companies, healthcare providers, and academic institutions to enhance cancer diagnostics, therapy selection, and biomarker identification.
Caris Life Sciences is targeting a valuation of up to $5.3 billion in its U.S. IPO, aiming to raise $423.5 million by selling over 23 million shares priced between $16 and $18 each.
Caris Life Sciences, headquartered in Irving, Texas, United States, was founded in 2008 by David Dean Halbert. In 2021, the company joined the unicorn club. With its data-driven approach and commitment to precision medicine, Caris Life Sciences continues to shape the future of cancer diagnostics and personalized treatment.
